Healthcare entity
All 1 tracked stories fall under one category: market-trends. First Defense is most often covered alongside ImmuCell, which appears in 1 of these 1 story. They are less corroborated than the beat average, carrying 2 original sources each against 2.5 for the same window.
Last mentioned: Mar 4, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: market-trends. First Defense is most often covered alongside ImmuCell, which appears in 1 of these 1 story. They are less corroborated than the beat average, carrying 2 original sources each against 2.5 for the same window. Their average consequence score of 5 runs below the beat's 5.9 for that window. First Defense appears in 1 tracked Healthcare story from March 4, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 22 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering First Defense. Shared-story counts are live from our verified record — not editorial picks.
ImmuCell (NASDAQ: ICCC) has reported its unaudited 2025 financial results, highlighting a pivotal year of production expansion and backlog reduction for its bovine immunology products. The results were released alongside strategic updates from Pinetree Capital, a major institutional investor, signaling a period of maturing corporate governance.
Source: finanznachrichten.de · manilatimes.net
First Defense is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
